help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Right arrow Return to article

TABLE 1. Clinical data

Patient Age (yr)/ sex Diagnosis Duration of alendronate treatment (yr) Other medications Incident fractures (yr on alendronate) Delayed/absent healing on alendronate (fracture site) Fracture healing yes/no (months off alendronate)

Group A
    1 55/F PO 6 Ca, D Sacrum (6) NA No (12)
    2 76/F PO 7 Ca, D Vertebra, rib (7) NA Yes (6)
    3 52/F POpen 8 Ca, D Femoral shaft (8) 4 months (femoral shaft) No (9)
    4 68/M IO 8 Ca, D Bilateral femoral shaft (8) NA No (8)
Group B
    5 68/F PO 3 E2, Ca, D Sacrum, ischium (3) 3 months (ischium) Yes (8)
    6 70/F PO 5 E2, Ca, D Pubic rami (3) 2 yr (pubic rami) Yes (4)
    7 67/F POpen 5 E2, Ca, D Bilateral femoral shaft (5) 9 months (left femoral shaft) Yes (5)
Group C
    8 49/F GIO (asthma) 3 Prednisone, Ca, D Proximal femur (1) 2 yr (femur) No (8)
    9 64/F GIO (fibromyalgia) 4 Prednisone, Ca, D Metatarsal, proximal femur (3) 8 months (proximal femur) Yes (3)

PO, Postmenopausal osteoporosis; POpen, postmenopausal osteopenia; IO, idiopathic osteoporosis; E2, estrogen; Ca, calcium; D, vitamin D; NA, not available or not applicable; F, female; M, male.





Right arrow Return to article


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals